Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

How can we achieve better prevention of progression to tuberculosis among contacts?

Steffen Geis, Gudrun Bettge-Weller, Udo Goetsch, Oswald Bellinger, Gisela Ballmann, Anja M. Hauri
European Respiratory Journal 2013 42: 1743-1746; DOI: 10.1183/09031936.00187112
Steffen Geis
1Hesse State Health Office, Dept for Health Protection, Dillenburg
2Postgraduate Training in Applied Epidemiology (PAE), Dept for Infectious Disease Epidemiology, Robert Koch-Institute, Berlin
3European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steffen.geis@yahoo.de
Gudrun Bettge-Weller
1Hesse State Health Office, Dept for Health Protection, Dillenburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Udo Goetsch
4Health Protection Authority of Frankfurt/Main, Frankfurt am Main
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oswald Bellinger
4Health Protection Authority of Frankfurt/Main, Frankfurt am Main
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisela Ballmann
5Health Protection Authority of Lahn-Dill-District Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anja M. Hauri
1Hesse State Health Office, Dept for Health Protection, Dillenburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Strategies for control and elimination of tuberculosis (TB) in low-incidence settings are directed toward treatment of recently acquired latent tuberculosis infection (LTBI) in TB contacts [1]. To identify this target population for preventive treatment the development of more specific, in vitro assays for LTBI, the interferon (INF)-γ release assays (IGRAs), has offered an alternative method for LTBI diagnosis. Although IGRAs are increasingly recommended in national guidelines, evidence that positive IGRA results are prognostic for developing TB is still limited [2, 3], especially outside of prospective studies with well-defined inclusion criteria. Therefore, we investigated progression towards active TB among IGRA positive contacts of active TB cases under routine field conditions and calculated the positive predictive value (PPV) for progression and the number needed to treat (NNT) with preventive treatment to prevent one incident TB case. Additionally, we introduced different cut-off values for IGRA positivity and compared the computed progression rates. Among all contacts with a positive tuberculosis-specific IGRA we describe the uptake of preventive treatment.

Our study covered a population of 3.2 million with a reported TB incidence of 7.5 cases per 100 000 population in 2008. From 2008 to 2010, we prospectively recruited all IGRA-positive contacts of newly detected sputum smear and/or culture positive notified TB cases at 12 local public health authorities (LPHAs) in Hesse, Germany. Only contacts with a history of TB disease were excluded.

The German recommendations for contact investigations, published in 2007 [4], served as the basis for the LPHAs investigations: a dual-step approach in which IGRA is only performed if the tuberculin skin test (TST) is positive. However, LPHAs deviated from this recommendation and performed TST in less than 27% of all IGRA tested contacts. All our study participants, namely all IGRA-positive contacts, were eligible for preventive treatment, usually with isoniazid for 6–9 months, and were closely monitored for active TB by the responsible LPHA for ∼1 year. During follow-up visits participants were asked about symptoms suggestive of active TB. If suspicion was aroused further investigations were carried out to confirm active TB, which we defined as clinically apparent disease requiring antituberculous treatment. All participants underwent chest radiography screening at completion of follow-up.

We used the commercially available IGRA: QuantiFERON-TB Gold In-Tube (Cellestis Limited, Carnegie, Australia) according to the manufacturer’s protocol. In addition to the manufacturer’s cut-off at 0.35 IU·mL−1 we compared different cut-off values (1.0 IU·mL−1 to >10.0 IU·mL−1) in our analysis possibly reflecting a higher mycobacterial load and higher risk for progression [5]. This might allow narrowing down the number of contacts eligible for preventive treatment, possibly resulting in more effective and accepted interventions.

We calculated TB incidence rate as the number of new cases per 100 person-years of observation and PPV as the number of incident TB cases per total number of participants, stratified by preventive treatment completion. To estimate the impact of preventive treatment we computed NNT as (1/PPV)/0.65 assuming an efficacy of 65% [6]. We used Stata 11 (Stata Corporation, College Station, TX, USA) for all statistical analyses. Data were pseudonymised for the investigators according to the requirements of the Hessian data protection office, Wiesbaden, Germany. Ethical approval in accordance with the Helsinki Declaration was not requested as only data collected during routine practices were obtained.

Of 1579 contacts 306 were IGRA-positive (cut-off ≥0.35 IU·mL−1) and enrolled in our study, 52 were lost during follow-up and excluded from further analysis. Among participants aged ≥15 years, 20% (47 out of 237) started preventive treatment, of whom 77% (36 out of 47) received a full-course. Preventive treatment was initiated in 11 (65%) out of 17 children aged <15 years. All 11 completed treatment.

During the follow-up period of the 207 IGRA-positive contacts who did not receive or did not complete preventive treatment six developed clinically apparent TB (characteristics shown in table 1), yielding a total TB incidence rate of 2.0 cases per 100 person-years (95% CI 0.7–4.4 cases per 100 person-years), a PPV of 2.9% and NNT of 52.8 contacts. None of the 47 contacts who completed preventive treatment developed TB, corresponding to a total TB incidence rate of 0.0 cases per 100 person-years (one-sided 97.5% CI 0.0–7.1 cases per 100 person-years). By using different cut-off values (table 2) the PPV progressively increased up to 9.3%, decreasing the NNT by two-thirds (NNT=16.6 contacts for a cut-off value of 10.0 IU·mL−1). However, one contact developing active TB was missed in cut-off values ≥3.0 IU·mL−1.

View this table:
  • View inline
  • View popup
Table 1– Characteristics of tuberculosis (TB) case contacts developing active TB in Hesse, Germany, 2008–2010
View this table:
  • View inline
  • View popup
Table 2– Changing values for positive predictive value (PPV) and number needed to treat (NNT) using different cut-off values for interferon-γ release assay (IGRA) positivity

Our study provides several important findings. First, uptake of preventive treatment was low in our study population. Secondly, a small fraction of the IGRA-positive contacts identified by routine contact investigation go on to progress towards active TB. Thirdly, raising the IGRA cut-off value to 2.0 IU·mL−1 would have reduced the number of contact persons receiving isoniazid without missing new incident cases.

Compared with similar studies described in the latest meta-analyses [2, 3] the overall uptake of preventive treatment was low in our study population, compromising the effectiveness of TB control efforts. Decreasing the failure of contacts with LTBI to accept or complete preventive treatment is the limiting factor for success. Although we did not collect data on reasons for declining preventive treatment, we assume that the major factor for this is the attending physician, who did not recommend treatment since only a minority of eligible contacts will develop TB [7]. In a recent study from the USA, only 17% of eligible subjects declined preventive treatment when it was recommended by the attending physician [8]. This assumption is strengthened by our observation of a high proportion of preventive treatment initiation in IGRA-positive children, suggesting that for this age group preventive treatment is perceived as having a favourable risk-benefit ratio.

When using the manufacturer’s IGRA cut-off value we observed similar progression rates to those previously reported [2, 3]. Particularly, our incidence rate is commensurate with an estimated incidence of 2.8 cases per 100 person-years in a large cohort of IGRA-positive contacts in Japan, a low prevalence country like Germany, in which no strict inclusion criteria to maximise the probability of contacts being infected was applied [9]. Given the low yield of progression to TB adjusting the cut-off value appears an appropriate procedure; the manufacturer’s recommended cut-off value was determined with data from 118 patients with culture-confirmed TB [10] and, therefore, might not be suitable for diagnosing recent latent infections having different immunological features. Diel et al. [11] observed a correlation between disease progression and IFN-γ levels. However, three out of 19 contacts who developed active TB had IFN-γ levels <1.0 IU·mL−1. Haldar et al. [12] did not find a difference when comparing the magnitude of IFN-γ levels and disease progression.

To reduce the burden of TB in low prevalence countries the current strategy of monitoring TB contacts remains an important backbone. Nevertheless, there is a need to improve the current risk–benefit ratio. Therefore, several strategies should be considered. Use of new cut-off values might convince medical doctors of the usefulness of preventive treatment when progression rates increase and NNT declines. Not only laboratory results, especially quantitative values to judge the magnitude of IGRA response, but also the contact’s medical and exposure history (e.g. immunosuppression, age, nature and degree of contact, chances of remote exposure to explain a positive IGRA) can influence the risk–benefit ratio. Firstly, this can overcome the inability of IGRAs to distinguish between recent and remote acquisition of LTBI, secondly stricter inclusion criteria for LTBI testing (e.g. duration of exposure or smear positivity) may increase the measured risk of progression among IGRA-positive contacts. In the future, contacts would benefit from preventive treatment regimens of shorter duration, with fewer side-effects that are currently being evaluated.

Our results are limited by the small number of IGRA-positive contacts at risk, the low number of individuals who developed active TB and the short follow-up time.

In conclusion, LTBI screening is a useful public health measure to identify a high-risk population for interventions like preventive treatment, health education or intensified surveillance. Nevertheless, the risk–benefit ratio has to be improved in order to convince attending physicians, as well as affected contacts, about the usefulness of preventive treatment. The most promising approach in our view would be to re-evaluate the recommended cut-off value in further studies and meta-analyses in order to improve IGRA testing for latent infection until more predictive biomarkers become available [2, 3].

Acknowledgments

We would like to express our gratitude to the staff of the following local public health authorities: Dietzenbach, Eschwege, Frankfurt am Main, Gelnhausen, Giessen, Herborn, Korbach, Limburg/Weilburg and Marburg. We thank Helmut Uphoff (Hesse State Health Office, Dillenburg, Germany), Katharina Alpers and Manuel Dehnert (both Robert Koch-Institute, Berlin, Germany) as well as all the EPIET coordinators for intellectual input and comments on the manuscript. We highly appreciate the technical support from H-J. Westbrock and J. Fitzenberger (Hesse State Health Office, Dillenburg, Germany).

Footnotes

  • Conflict of interest: None declared.

  • Received November 18, 2012.
  • Accepted June 17, 2013.
  • ©ERS 2013

References

  1. ↵
    1. Broekmans JF,
    2. Migliori GB,
    3. Rieder HL,
    4. et al
    . European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765–775.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Diel R,
    2. Loddenkemper R,
    3. Nienhaus A
    . Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63–75.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rangaka MX,
    2. Wilkinson KA,
    3. Glynn JR,
    4. et al
    . Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45–55.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Diel R,
    2. Forssbohm M,
    3. Loytved G,
    4. et al
    . Empfehlungen fur die Umgebungsuntersuchungen bei Tuberkulose. [Recommendations for background studies in tuberculosis]. Pneumologie 2007; 61: 440–455.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Böttger EC
    . Interferon-γ release assays and the risk of developing active tuberculosis. Am J Respir Crit Care Med 2012; 185: 786–787.
    OpenUrlPubMed
  6. ↵
    Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60: 555–564.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Comstock GW,
    2. Livesay VT,
    3. Woolpert SF
    . The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131–138.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Horsburgh CR Jr.,
    2. Goldberg S,
    3. Bethel J,
    4. et al
    . Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137: 401–409.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Yoshiyama T,
    2. Harada N,
    3. Higuchi K,
    4. et al
    . Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. Int J Tuberc Lung Dis 2010; 14: 819–827.
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Mori T,
    2. Sakatani M,
    3. Yamagishi F,
    4. et al
    . Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59–64.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Diel R,
    2. Loddenkemper R,
    3. Niemann S,
    4. et al
    . Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011; 183: 88–95.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Haldar P,
    2. Thuraisingam H,
    3. Patel H,
    4. et al
    . Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 2013; 68: 240–246.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 6 Table of Contents
European Respiratory Journal: 42 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How can we achieve better prevention of progression to tuberculosis among contacts?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
How can we achieve better prevention of progression to tuberculosis among contacts?
Steffen Geis, Gudrun Bettge-Weller, Udo Goetsch, Oswald Bellinger, Gisela Ballmann, Anja M. Hauri
European Respiratory Journal Dec 2013, 42 (6) 1743-1746; DOI: 10.1183/09031936.00187112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
How can we achieve better prevention of progression to tuberculosis among contacts?
Steffen Geis, Gudrun Bettge-Weller, Udo Goetsch, Oswald Bellinger, Gisela Ballmann, Anja M. Hauri
European Respiratory Journal Dec 2013, 42 (6) 1743-1746; DOI: 10.1183/09031936.00187112
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society